Lats-IN-1
(Synonyms: Lats-IN-1) 目录号 : GC61527
LATS-IN-1是LATS1和LATS2的抑制剂（IC50均为2nM）。Lats-IN-1抑制核心Hippo通路激酶，并激活下游效应分子YAP/TAZ，使其转位至细胞核，从而驱动促进细胞增殖和存活的基因表达。Lats-IN-1主要用于治疗组织再生和退行性疾病。
Cas No.:1424635-83-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
LATS-IN-1 is an inhibitor of LATS1 and LATS2 (IC50 = 2nM for both). Lats-IN-1 inhibits core Hippo pathway kinases and activates downstream effector molecules YAP/TAZ, which translocate to the nucleus, driving expression of genes that promote cell proliferation and survival. Lats-IN-1 is primarily used to treat tissue regeneration and degenerative diseases [1-4].
In HEK293A cells, LATS-IN-1 (10μM, 24h) inhibits phosphorylation of YAP1 in serum-starved HEK293A cells (EC50 = 510 nM) [1]. In K562 cells, LATS-IN-1 (30μM, 48h) significantly reduces the number of K562 colonies in the colony formation assay [5]. In human embryonic stem cells, LATS-IN-1 (30μM, 24h) inhibition of the Hippo Pathway Promotes Growth of ATM-Knockout human embryonic stem cells and of Their Derived NPCs [6]. In MCF-7 cells, the proliferation and migration ability of MCF-7 cells was significantly restored after LATS-IN-1 (30μM, 24h) inhibited the Hippo signaling [7]. In LX2 cells, Lats-IN-1 (5μM, 24h) was supplemented, expression of YAP and α-SMA was increased in Ctrl (scrambled)-siRNA-transfected LX2 cells [8].
In a subcutaneous xenograft tumor mouse model of 4T1 cells, LATS-IN-1 (10mg/kg, sc, 7d) increases xenograft tumor growth [7]. In myocardial infarction mice models, Lats-IN-1 (1mg/kg, ip, 14d) treated mice had higher ejection fraction (EF%) and fractional shortening (FS%) than those treated with the vehicle [9]. In lumbar spine instability surgery mice modes Lats-IN-1 (3mg/kg, ip, 56d) treated mice showed less pores or remodeling related signs in the cartilage endplate, with abundant Collagen II expression and rare Collagen X expression [10]. In vascular smooth muscle cell-specific Ddr1 knockout mice, Lats-IN-1 (0.5mg/kg, ip, 7d) abolishes the effect of DDR1-IN-1 on the inhibition of YAP activation [11].
References:
[1]. Kastan N, Gnedeva K, Alisch T, et al. Small-molecule inhibition of Lats kinases may promote Yap-dependent proliferation in postmitotic mammalian tissues. Nature communications. 2021 May 25; 12(1): 3100.
[2]. Cai X, Warburton C, Perez OF, et al. Hippo signaling modulates the inflammatory response of chondrocytes to mechanical compressive loading. bioRxiv. 2023 Jun 11.
[3]. Boopathy GT, Hong W. Role of hippo pathway-YAP/TAZ signaling in angiogenesis. Frontiers in cell and developmental biology. 2019 Apr 10; 7: 49.
[4] Ohnishi Y, Masui A, Suezawa T, et al. Screening of factors inducing alveolar type 1 epithelial cells using human pluripotent stem cells. Stem cell reports. 2024 Apr 9; 19(4): 529-544.
[5]. Klaihmon P, Lorthongpanich C, Kheolamai P, et al. Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib. Scientific Reports. 2024 Feb 18; 14(1): 3993.
[6]. Viner-Breuer R, Golan-Lev T, Benvenisty N, et al. Genome-Wide Screening in Human Embryonic Stem Cells Highlights the Hippo Signaling Pathway as Granting Synthetic Viability in ATM Deficiency. Cells. 2023 May 29; 12(11): 1503.
[7]. Chen Y, Li J, Pu L, et al. DNAJB4 suppresses breast cancer progression and promotes tumor immunity by regulating the Hippo signaling pathway. Discover Oncology. 2023 Aug 7; 14(1): 144.
[8]. Xie L, Chen H, Zhang L, et al. JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis. Clinical and Molecular Hepatology. 2024 Jan 8; 30(2): 206.
[9]. Shen H, Wang Q, Liu B, et al. Lats-IN-1 protects cardiac function and promotes regeneration after myocardial infarction by targeting the hippo pathway. Frontiers in Pharmacology. 2024 Oct 3; 15: 1463465.
[10]. Li H, Tang Y, Liu Z, et al. Lumbar instability remodels cartilage endplate to induce intervertebral disc degeneration by recruiting osteoclasts via Hippo-CCL3 signaling. Bone Research. 2024 May 30; 12(1): 34.
[11]. Liu J, Wang J, Liu Y, et al. Liquid-liquid phase separation of DDR1 counteracts the hippo pathway to orchestrate arterial stiffening. Circulation Research. 2023 Jan 6; 132(1): 87-105.
LATS-IN-1是LATS1和LATS2的抑制剂（IC50均为2nM）。Lats-IN-1抑制核心Hippo通路激酶，并激活下游效应分子YAP/TAZ，使其转位至细胞核，从而驱动促进细胞增殖和存活的基因表达。Lats-IN-1 主要用于治疗组织再生和退行性疾病 [1-4]。
在HEK293A细胞中，LATS-IN-1（10μM，24h）可抑制血清饥饿HEK293A细胞中YAP1的磷酸化（EC50 = 510nM） [1]。在K562细胞中，LATS-IN-1（30μM，48h）在集落形成实验中显著减少K562细胞集落的数量 [5]。在人类胚胎干细胞中，LATS-IN-1（30μM，24h)抑制Hippo通路可促进ATM基因敲除的人类胚胎干细胞及其衍生的NPC的生长 [6]。在MCF-7细胞中，LATS-IN-1（30μM，24h）抑制Hippo信号通路后，MCF-7细胞的增殖和迁移能力显著恢复 [7]。在LX2细胞中，补充Lats-IN-1（5μM，24h）后，Ctrl(scrambled)-siRNA转染的LX2细胞中YAP和α-SMA的表达增加 [8]。
在4T1细胞皮下移植瘤小鼠模型中，LATS-IN-1（10mg/kg，ip，7d）可促进异种移植肿瘤的生长 [7]。在心肌梗死小鼠模型中，Lats-IN-1（1mg/kg，ip，14d）治疗小鼠的射血分数（EF%）和缩短分数（FS%）均高于对照组[9]。在腰椎不稳手术小鼠模型中，Lats-IN-1（3mg/kg，ip，56d）治疗小鼠的软骨终板孔隙或重塑相关征象减少，II型胶原蛋白表达丰富，X型胶原蛋白表达稀少 [10]。在血管平滑肌细胞特异性Ddr1基因敲除小鼠中，Lats-IN-1（0.5mg/kg，ip，7d）可消除DDR1-IN-1对YAP活化的抑制作用 [11]。
| Kinase experiment [1]: | |
Preparation Method | The LATS-IN-1 kinase assay uses an in vitro kinase activity detection method, using recombinant Lats1 and Lats2 proteins containing the main kinase domain, and STK1 peptides known to be phosphorylated by them as substrates. Gradient concentrations of LATS-IN-1 are added under different ATP concentrations (10, 50, 250μM). After the reaction system is configured, incubate for 1h. The degree of substrate phosphorylation is detected by fluorescence or FRET and the IC₅₀ value is calculated. |
Reaction Conditions | 0.01nM-1μM; 1h |
Applications | The IC₅₀ of TRULI against Lats1/2 is 0.2nM at 10μM ATP, and the IC₅₀ increases accordingly with increasing ATP concentration, TRULI is an ATP-competitive Lats kinase inhibitor. |
| Cell experiment [1]: | |
Cell lines | HEK293A cells |
Preparation Method | HEK293A cells were plated overnight in 96-well culture plates at a density of 50,000 cells per well in the medium described above. To start the assay, new serum-free medium with 10μM LATS-IN-1 was added to the cells, which were then incubated for 24h at 37 °C. |
Reaction Conditions | 10μM; 24h |
Applications | Lats-IN-1 inhibits YAP phosphorylation and promotes YAP nuclear translocation, activating its downstream transcriptional activity. |
| Animal experiment [2]: | |
Animal models | Myocardial infarction (MI) mice models |
Preparation Method | The mice in the Sham + Lats-IN-1 group and the MI + Lats-IN-1 group were administered intraperitoneally with Lats-IN-1 (1mg/kg) dissolved in corn oil on the first day after myocardial infarction surgery, while the mice in the Sham + Vehicle group and the MI + Vehicle group were given corn oil. Following a period of 2 weeks post-MI, the mice were anesthetized and subsequently sacrificed to facilitate the collection of heart tissues for subsequent examinations and analyses. |
Dosage form | 1mg/kg; ip; 14d |
Applications | Lats-IN-1 treated mice had higher ejection fraction (EF%) and fractional shortening (FS%) than those treated with the vehicle. |
References: | |
| Cas No. | 1424635-83-5 | SDF | |
| 别名 | Lats-IN-1 | ||
| Canonical SMILES | O=C(C1=CNC2=NC=CC=C12)/N=C(SC=C3)/N3CC4=CC=CC=C4 | ||
| 分子式 | C18H14N4OS | 分子量 | 334.39 |
| 溶解度 | DMSO: 83.33 mg/mL (249.20 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9905 mL | 14.9526 mL | 29.9052 mL |
| 5 mM | 0.5981 mL | 2.9905 mL | 5.981 mL |
| 10 mM | 0.2991 mL | 1.4953 mL | 2.9905 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet